Diagnostics firm Alveo Technologies announced that it has developed a rapid, point-of-need diagnostic for avian influenza that can detect the H5N1 variant based on sequences published from recent human infections in Colorado and those found in infected cattle.
In a statement, Alveo said that the Flockscreen LAMP Avian Influenza Molecular Test can accurately detect the presence of the virus in both cloacal and oropharyngeal samples from poultry. The firm and its development partners performed more than 20,000 reactions on over 4,000 assay cartridges during their evaluation of over 100 candidate primer sets and assay conditions using both contrived and clinical samples, Alveo added.
Alveo said that the Flockscreen LAMP Avian Influenza Molecular Test is available for presale now in the European Union (EU) and the Middle East; the firm expects to begin shipping to the EU and the Middle East in the third quarter of 2024 once validation and verification activities have concluded with the relevant regulatory bodies. The company is working to validate avian influenza diagnostics for human and bovine use, it said.
